Observational studyAddiction biology2026
The Predictive Value of Tenascin-C, Neopterin and Pro-Inflammatory Cytokines (IFN-γ, TNF-α, IL-6) in Alcohol Use Disorder Treatment Response.
Observational study in Addiction biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The underlying neurobiological mechanisms of chronic alcohol consumption, particularly neuroinflammation and immune system dysregulation, have been extensively studied in recent years. In this process, the identification of objective biomarkers that can predict treatment response and enable personalized medicine approaches is of critical importance. This study aimed to evaluate the potential predictive value of tenascin-C (TNC), an extracellular matrix protein, neopterin, a marker of cellular immune activation and pro-inflammatory cytokines interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), during the treatment process for alcohol use disorder (AUD). This prospective observational cohort study included 30 patients admitted to an AUD treatment centre and 31 healthy controls. Serum TNC, IL-6, TNF-α and IFN-γ levels were measured using the ELISA method. Clinical outcomes were assessed using the SCL-90-R and API-K scales. Serum samples were collected from patients at admission and on the 7th day of detoxification treatment. Baseline serum TNC levels in the alcohol group (131.78 ± 50.92 ng/mL) were significantly higher than in the healthy control group (63.92 ± 23.85 ng/mL). In the alcohol group, TNC (p = 0.007) and AST (p = 0.025) levels decreased significantly, while vitamin B12 (p = 0.002) and platelet count (p = 0.012) increased. No significant difference was observed in neopterin and cytokine levels (TNF-α, IL-6 and IFN-γ) between baseline and follow-up measurements. Clinical assessments showed significant improvements in depression (p = 0.041), anxiety (p = 0.014) and total symptom scores (p = 0.026) on the SCL-90-R scale. ROC analysis showed that a reduction of 28.22% or more in TNC predicted clinical improvement with an overall accuracy rate of 73.33%.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.